These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 7438892

  • 1. Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.
    Burns ER, Scheving LE.
    Chronobiologia; 1980; 7(1):41-51. PubMed ID: 7438892
    [No Abstract] [Full Text] [Related]

  • 2. Combined chronochemotherapy of L1210 leukemic mice using 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine, methylprednisolone and cis-diamminedichloroplatinum.
    Scheving LE, Burns ER, Halberg F, Pauly JE.
    Chronobiologia; 1980; 7(1):33-40. PubMed ID: 7192203
    [Abstract] [Full Text] [Related]

  • 3. Survival and cure of leukemic mice after circadian optimization of treatment with cyclophosphamide and 1-beta-D-arabinofuranosylcytosine.
    Scheving LE, Burns ER, Pauly JE, Halberg F, Haus E.
    Cancer Res; 1977 Oct; 37(10):3648-55. PubMed ID: 908013
    [Abstract] [Full Text] [Related]

  • 4. Sequential administration of two oncostatic drugs: study of modalities for pharmacodynamic potentiation.
    Pouillart R, Huong TH, Brugerie E, Lheritier J.
    Biomedicine; 1974 Dec 10; 21(12):471-9. PubMed ID: 4462870
    [No Abstract] [Full Text] [Related]

  • 5. Combination chemotherapy in sequence for the treatment of L1210 leukemia.
    Roberts D, Hilliard SL.
    Cancer Res; 1978 Aug 10; 38(8):2317-20. PubMed ID: 667827
    [No Abstract] [Full Text] [Related]

  • 6. Single versus combination chemotherapy of L1210 leukemia.
    Koza I, Balázová E, Ujházy V.
    Neoplasma; 1980 Aug 10; 27(6):691-6. PubMed ID: 7254424
    [Abstract] [Full Text] [Related]

  • 7. Chronochemotherapy of L1210 leukemic mice with cytosine arabinoside or cyclophosphamide.
    Rose WC, Trader MW, Laster WR, Schabel FM.
    Cancer Treat Rep; 1978 Sep 10; 62(9):1337-49. PubMed ID: 688277
    [No Abstract] [Full Text] [Related]

  • 8. Optimum time sequence for the administration of vincristine and cyclophosphamide in vivo.
    Razek A, Vietti T, Valeriote F.
    Cancer Res; 1974 Aug 10; 34(8):1857-61. PubMed ID: 4842737
    [No Abstract] [Full Text] [Related]

  • 9. Circadian bioperiodic response of mice bearing advanced L1210 leukemia to combination therapy with adriamycin and cyclophosphamide.
    Scheving LE, Burns ER, Pauly JE, Halberg F.
    Cancer Res; 1980 May 10; 40(5):1511-5. PubMed ID: 7370988
    [No Abstract] [Full Text] [Related]

  • 10. [L 1210 leukemia, an experimental model for the potentiation of drugs used for acute leukemias].
    Pouillart P, Huong TH, Lhéritier J.
    Bull Cancer; 1974 May 10; 61(4):509-26. PubMed ID: 4458834
    [No Abstract] [Full Text] [Related]

  • 11. Combination therapy of mouse leukemia L1210 by 1-beta-D-arabinofuranosylcytosine and 6-[(4-nitrobenzyl)thio]-9-beta-D-ribofuranosylpurine.
    Cass CE, Muzik H, Paterson AR.
    Cancer Res; 1975 May 10; 35(5):1187-93. PubMed ID: 1120308
    [Abstract] [Full Text] [Related]

  • 12. Chemotherapy of leukemia L1210 in mice with 1-beta-d-arabinofuranosylcytosine hydrochloride. I. Influence of treatment schedules.
    Kline I, Venditti JM, Tyrer DD, Goldin A.
    Cancer Res; 1966 May 10; 26(5):853-9. PubMed ID: 5936445
    [No Abstract] [Full Text] [Related]

  • 13. Schedule-dependent synergism for the combination of 1-beta-D-arabinofuranosylcytosine and daunorubicin.
    Edelstein M, Vietti T, Valeriote F.
    Cancer Res; 1974 Feb 10; 34(2):293-7. PubMed ID: 4810905
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Chronochemotherapy: L 1210 leukemia and beyond.
    Halberg F, Nelson W, Cornélissen G, Haus E, Scheving LE, Good RA.
    Chronobiologia; 1979 Feb 10; 6(3):203-11. PubMed ID: 520097
    [Abstract] [Full Text] [Related]

  • 16. [Chemotherapy of L1210 leukemia: comparison of 7 drugs given either continuously for 20 days, or in a single massive dose, early or late].
    Mathé G, Schwarzenberg L, Hayat M, Schneider M.
    Rev Fr Etud Clin Biol; 1968 Dec 10; 13(10):951-60. PubMed ID: 5306738
    [No Abstract] [Full Text] [Related]

  • 17. N4-Behenoyl-1-beta-D-arabinofuranosylcytosine as a potential new antitumor agent.
    Aoshima M, Tsukagoshi S, Sakurai Y, Oh-ishi JI, Ishida T.
    Cancer Res; 1977 Aug 10; 37(8 Pt 1):2481-6. PubMed ID: 872077
    [Abstract] [Full Text] [Related]

  • 18. On methods for testing and achieving cancer chronotherapy.
    Halberg F, Nelson W, Cornelissen G, Haus E, Scheving LE, Good RA.
    Cancer Treat Rep; 1979 Aug 10; 63(8):1428-30. PubMed ID: 476717
    [No Abstract] [Full Text] [Related]

  • 19. Electronic volume analysis of L1210 chemotherapy.
    Zucker RM, Helfman D.
    Cancer Res; 1976 Dec 10; 36(12):4434-8. PubMed ID: 1000492
    [Abstract] [Full Text] [Related]

  • 20. Effects of 2'-deoxycoformycin, 9-beta-D-arabinofuranosyladenine 5'-phosphate, and 1-beta-D-arabinofuranosylcytosine triple combination therapy on intracerebral leukemia 1210.
    Caron N, Lee SH, Kimball AP.
    Cancer Res; 1977 Sep 10; 37(9):3274-9. PubMed ID: 884674
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.